The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
Open accessAbstract
Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18.2(CLDN18.2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function. Its characteristic widespread expression in tumour tissues and its exposed extracellular loops make it an ideal target for researchers to develop targeted strategies and immunotherapies for cancers of the GI tract. In the present review, we focus on the expression pattern of CLDN18.2 and its clinical significance in GI cancer. We also discuss the tumour-promoting and/or tumour-inhibiting functions of CLDN18.2, the mechanisms regulating its expression, and the current progress regarding the development of drugs targeting CLDN18.2 in clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several CLDN18.2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“3 HER2/HER3 signalling pathway The HER family consists of four membrane-bound tyrosine kinase receptors with similar structures: HER1 (EGFR), HER2, HER3, and HER4 (63).”
BackgroundComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672 · cited 1×
“4 MicroRNA MicroRNAs (miRNAs) are a large family of small endogenous regulatory RNAs that regulate posttranscriptional regulators of gene expression (67, 68).”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Lu, T. X., & Rothenberg, M. E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.034 · Cited by 2,425
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., & Tsukita, S. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1539 · Cited by 2,095
Global Burden of 5 Major Types of Gastrointestinal Cancer
Arnold, M., Abnet, C. C., Neale, R. E., Vignat, J., Giovannucci, E. L., McGlynn, K. A., & Bray, F. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.068 · Cited by 2,027 · cited 1×
“4 million cancer-related deaths worldwide in 2018; these numbers correspond to over one-quarter (26%) of global cancer cases and over one-third (35%) of all cancer-related deaths (1).”
BackgroundBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Cited by
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
BackgroundClaudin 18.2 as a novel therapeutic target
Nakayama, I., Qi, C., Chen, Y., Nakamura, Y., Shen, L., & Shitara, K. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00874-2 · Cited by 210
“The downstream target, activator protein AP-1, has been shown to enhance the translation of claudin 18.2 mRNAs in gastric, pancreatic and bile duct cancer cells 68–70”
InfluentialRecent Advancement in mRNA Vaccine Development and Applications
Al Fayez, N., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 167
Fassan, M., Kuwata, T., Matkowskyj, K. A., Röcken, C., & Rüschoff, J. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100589 · Cited by 72
Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
Mathias-Machado, M. C., de Jesus, V. H. F., Jacome, A. A. D. A., Donadio, M. D. S., Aruquipa, M. P. S., de Farias, J. P. F., Cunha, R., Silva, L. M. D., & Peixoto, R. D. (2024) · Cancers · doi:10.3390/cancers16030679 · Cited by 79
“…in the TJs [25,32–34] and regulates the permeability to both Na+ and H+ in gastric acid by functioning as a barrier in the gastric mucosa [35], playing a role in cellular polarity, retaining a barrier function, as well as promoting resistance to gastric acid [36]. gastric epithelial cells, CLDN18.”
Background
Metadata
- Authors
- Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X.
- Affiliations
- Zhejiang Cancer Hospital (CN)
- Corresponding author
- Cheng, Xiangdong
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-10
- Volume
- 13
- Pages
- 1132319-1132319
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC10036590
- OpenAlex
- W4323860370
- Cited by
- 78
- References
- 102
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 32 · 2023: 4
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82074245, 81973634)
- Natural Science Foundation of Zhejiang Province (HDMY22H160008)
- Medical Science and Technology Project of Zhejiang Province (2022KY114, WKJ-ZJ-2104)
- Postdoctoral Research Foundation of China (2022M713203)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- claudin 18.2, gastrointestinal cancer, targeted therapy, immunotherapy, tight junctions, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. https://app.cochat.ai/papers/10.3389/fonc.2023.1132319
- The paper
- Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023). Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Frontiers in Oncology. https://doi.org/10.3389/fonc.2023.1132319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.